



Written submission from Isologic Innovative Radiopharmaceuticals

Mémoire d'Isologic Innovative Radiopharmaceuticals

In the Matter of

À l'égard de

McMaster University

Université McMaster

Application to renew its McMaster Nuclear
Reactor Class IA non-power reactor operating
licence

Demande concernant le renouvellement de son
permis d'exploitation d'un réacteur de catégorie
IA non producteur de puissance pour le réacteur
nucléaire McMaster

Public Hearing - Hearing in writing based on
written submissions

Audience publique - Audience fondée sur des
mémoires

April 2024

Avril 2024

RE: McMaster University Research Reactor Licence Renewal (Licence #NPROL-01)

Dear Commission member,

I am writing on behalf of Isologic Innovative Radiopharmaceuticals (IIR) and as the company's corporate RSO in support of the McMaster University Research Reactor Licence renewal (#NPROL-01).

McMaster is Canada's Nuclear University. It is home to a world-class suite of nuclear research facilities anchored by the McMaster Nuclear Reactor (MNR), built in 1959. These facilities enable discoveries in nuclear medicine, clean energy, and materials science, while providing unique educational opportunities for students, including those in nuclear science and engineering.

Many of the services offered by MacMaster Nuclear have a far-reaching impact on many industries, however, this letter only covers the ones directly affecting IIR and the radiation safety community.

IIR has directly benefitted from the services provided by the McMaster University Research Reactor for such things as helping to confirm the purity of our products, to help provide neutron activation sample analysis assisting our decisions making process for new facility construction materials, as well as to confirm that our radioiodine air emission sampling system is functioning well.

Without the support from MacMaster's nuclear services and educational program, Isologic and the community become negatively impacted by the following:

- Loss of support for our business which provides quality medical care.
- Loss of sharing of best practices.
- Loss of qualified individuals to run our nuclear-related industries, including radiation safety.

Sincerely,



Valerie A. Phelan, MSc, CRPA_R | Corporate RSO
ISOLOGIC Innovative Radiopharmaceuticals | Mobile 416-522-5576
valerie.phelan@isologicradiopharm.ca